A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States

NCT06851065 · clinicaltrials.gov ↗

COMPLETED

Status

418

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Luspatercept
DRUG: Erythropoiesis-stimulating agents

Sponsor

Bristol-Myers Squibb